Trial Profile
NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Apr 2021
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary) ; Everolimus
- Indications Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders
- Focus Therapeutic Use
- Acronyms NEXT
- 09 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Mar 2014 Results for vascular healing presented at the 63rd Annual Scientific Session of the American College of Cardiology.
- 28 Sep 2012 New source identified and integrated (University Hospital Medical Information Network, UMIN000004661)